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Molecular imaging: novel tools in visualizing
rheumatoid arthritis
A. Wunder, R. H. Straub, S. Gay1, J. Funk and U. Mu¨ller-Ladner
Molecular imaging is a rapidly emerging ﬁeld in biomedical research, aiming at the visualization, characterization and
quantiﬁcation of molecular and cellular processes non-invasively within intact living organisms. To sense biological processes
such as gene expression, angiogenesis, apoptosis or cell trafﬁcking in vivo, imaging reporter agents that interact speciﬁcally
with molecular targets and appropriate imaging systems are currently under development. In rheumatoid arthritis, these
novel tools will be used to evaluate physiological and pathophysiological processes, to facilitate diagnosis and monitor
therapeutic regimens, to enable reliable prognosis and to support the development of new therapies. In this review, we
summarize the basic principles of molecular imaging, such as the development of molecular imaging agents, the actual
capabilities of different imaging modalities and the most recent advances in molecular imaging, demonstrating the potential
of this technology. With regard to their applicability in rheumatic diseases, we discuss potential molecular targets, current
experimental approaches and the future prospects for molecular imaging in rheumatoid arthritis.
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Background
Diagnosis and monitoring of rheumatoid arthritis (RA) by
imaging techniques is difﬁcult and restricted almost exclusively
to the anatomical level. The majority of current imaging
methods used in clinical medicine, especially radiography, X-ray
computed tomography (CT), magnetic resonance tomography
(MRT) and ultrasound, rely predominantly on energy/tissue
interactions. Most contrast agents are unspeciﬁc and do not
interact with speciﬁc molecular targets. Therefore, the contrast
necessary for (computerized) visualization to differentiate patho-
logical from normal tissue is based on anatomical, physiological
or metabolic heterogeneity rather than identifying speciﬁc
cellular or molecular events that underlie disease. In RA,
articular bone erosion and joint space narrowing are relatively
well delineated by conventional radiography. In the past, high-
resolution ultrasound, and especially MRT, have improved
substantially the ability to detect and visualize initial destruction
during the ﬁrst stages of RA, sometimes even preceding the
clinical symptoms necessary to establish diagnosis, but still
report relatively late in the course of the disease and do
not provide any information about cellular and molecular
mechanisms [1–3].
Recent advances in the molecular basis of disease, the
development of target-speciﬁc imaging agents, and new devel-
opments in the ﬁeld of imaging are increasingly allowing the
non-invasive evaluation of cellular and molecular events, such
as gene expression, angiogenesis, apoptosis and cell trafﬁcking,
within the context of physiologically authentic environments
of living organisms. This technology, called molecular imaging,
has its roots in nuclear medicine, which uses tracers that bind
speciﬁcally to molecular targets [4–6].
Cellular and molecular changes often occur a long time
before any signs of anatomical, physiological or metabolic
changes become evident. Therefore, non-invasive visualization
and quantitation of biological processes at the molecular level
facilitates earlier detection, and furthermore it provides more
detailed information about basic molecular events involved
in disease compared with conventional imaging methods.
Consequently, molecular imaging is a promising tool for the
evaluation of physiology and pathophysiology. It enables a more
fundamental understanding of key processes, for earlier and
more reliable prognosis, earlier assessment of treatment response
and the development of new therapies, which are urgently
needed in many diseases. Molecular imaging technologies are
currently being developed, based not only based on nuclear
medicine techniques, but also on MRT, ultrasound and the
emerging ﬁeld of optical imaging. They will have a profound
impact in research and the clinical management of numerous
disorders, including cancer and cardiovascular, neurological and
inﬂammatory diseases [4–6].
In RA, monitoring of speciﬁc biological processes, such as
inﬂammatory and destructive pathways, in experimental arthritis
models and in human disease would undoubtedly be very helpful
for both basic research in arthritis and the clinical management
of patients. The development of molecular imaging methods is
a challenging multistep process, especially in RA. Of particular
importance is the development of molecular imaging agents
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enabling the analysis of pathophysiological events crucial in
disease and the choice of an adequate imaging modality
applicable in clinical settings [7, 8].
Development of novel molecular imaging agents
The design of molecular imaging agents is demanding because
numerous critical issues need to be addressed: (i) of the
multitude of extra- and intracellular processes in RA, the iden-
tiﬁcation of a suitable molecular target by target screening
and veriﬁcation at the subcellular, cellular and tissue level is
mandatory; (ii) a ligand that binds to this molecular target with
high speciﬁcity and afﬁnity by ligand screening needs to be
identiﬁed; (iii) this ligand needs to be labelled with a signal
molecule for visualization depending on the imaging modality
used to sense the imaging agent; (iv) biological barriers for
the imaging agents during on the way to the molecular target
must be overcome not only in vitro but also in vivo; and
(v) strategies for signal ampliﬁcation in order to increase
sensitivity need to be established. The ﬁnal steps in the
development of molecular imaging strategies are clinical trials
to verify and validate clinical applicability and practical
utilization in human disease (Fig. 1) [4–6].
Imaging agents can be subdivided into three categories:
non-speciﬁc probes, targeted probes, and activatable probes
(Fig. 2).
Non-speciﬁc imaging agents
These have compartmental distributions and do not interact
with a speciﬁc molecular target. They accentuate dissimilarities
between tissues, such as differences in permeability or perfusion,
and are helpful in characterizing physiological processes such
as blood volume, ﬂow or perfusion [9]. In RA, the synovium of
inﬂamed joints shows a large number of capillaries, enhanced
capillary perfusion and permeability. After intravenous injection,
higher amounts of unspeciﬁc contrast agents can therefore be
detected in arthritic synovium compared with surrounding
healthy tissue or normal synovium. The rate and magnitude of
synovial enhancement on magnetic resonance images (MRIs)
after intravenous injection of (non-speciﬁc) gadolinium diethyl-
enetriamine pentaacetic acid (Gd-DTPA) contrast agents has
been shown to correlate with disease activity and is sensitive to
therapy-induced changes. This demonstrates that non-speciﬁc
contrast agents can be beneﬁcial in assessing crucial parameters
in clinical management [1–3].
FIG. 1. Principle of molecular imaging and the development of molecular imaging agents. In order to visualize molecular
events non-invasively, imaging agents need to be designed that interact speciﬁcally with appropriate molecular targets involved in
the pathophysiology of disease. This includes markers for early diagnosis, the stage or the severity of disease, treatment efﬁcacy
or prognosis. Once a suitable target has been deﬁned, a ligand that binds to the target with high afﬁnity and speciﬁcity needs
to be designed. Depending on the imaging modality, a signal molecule (label), such as a radioisotope for nuclear imaging,
a ﬂuorochrome for optical imaging, a magnetic particle for MRT, an acoustic reﬂective compound for ultrasound or a high-
atomic-number atom that absorbs X-rays (e.g. iodine) for CT, has to be linked to the ligand, facilitating the sensitive
detection of the imaging agent in a clinical setting. Finally, the acquired images need to be reconstructed and processed using
computer systems.
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Targeted imaging agents
These are usually created by coupling a signal molecule to
afﬁnity a ligand, such as an antibody, antibody fragment,
peptide, a small molecule or a larger multivalent construct. This
ligand binds with high speciﬁcity to a certain target which might
be, for instance, a receptor [9]. In RA, this kind of imaging agent
can be used to evaluate receptor expression and distribution
(e.g. imaging of cytokine receptors involved in disease) [7, 8].
Shortcomings of targeted imaging agents are that both the
unbound and the non-speciﬁcally bound fractions of an agent
produce a signal, potentially resulting in high background noise.
In addition, targeted imaging agents require a certain amount
of time for washout. To improve the sensitivity of the imaging
method, signal ampliﬁcation strategies, such as pretargeting
and avidin–biotin ampliﬁcation, can be used to boost target/
background ratios. Additional efforts to improve the attributes
of an imaging agent include optimization of pharmacological
properties [9].
Activatable imaging agents (‘smart’ or ‘responsive’ probes)
These undergo a physicochemical change after interacting with
their intended target. In their native injected state, they are
almost undetectable. Upon target interaction, the detectable
signal increases substantially. Since one target molecule (enzyme)
can activate several molecules of the imaging probe, an enormous
signal ampliﬁcation occurs, resulting in high signal-to-noise
ratios through background suppression. Activatable imaging
agents have been developed for MRT and ﬂuorescence
imaging. Examples of such agents include protease-sensitive
imaging probes, which are activated upon enzymatic
cleavage [9]. In RA, these probes can be used for monitoring
the activity of matrix-degrading enzymes, such as matrix
metalloproteinases (MMPs) and cathepsins [7, 9].
Imaging modalities
Various imaging modalities, such as conventional radiography,
CT, ultrasound, MRT, nuclear imaging methods such as single
photon emission computed tomography (SPECT) and positron
emission tomography (PET), as well as other methods, including
optical imaging methods such as ﬂuorescence imaging and
bioluminescence imaging, are available. In ﬂuorescence imaging,
light emitted by a ﬂuorochrome (ﬂuorescence) upon excitation
by a light source is detected by sensitive cameras, whereas
in bioluminescence imaging no excitation light is necessary.
Bioluminescence imaging is based on the expression of luciferase
by transfected cells, which catalyses the oxidation of luciferin
and results in the release of photons. In case of ﬂuorescence
imaging, several modalities are available, e.g. ﬂuorescence
reﬂectance imaging (FRI; the light source and the detector are
on the same side of the subject; 2-dimensional images) and
ﬂuorescence-mediated tomography (FMT; the subject is illumi-
nated by different sources and the emitted light is captured by
multiple detectors; 3-dimensional images) [4–6, 9].
The imaging methods differ with respect to spatial resolution,
the ability to produce 3-dimensional images, depth limit,
sensitivity, the possibility of quantiﬁcation, the availability
of imaging agents, the potential to gather information at
the anatomical, physiological, cellular and molecular levels,
costs and effort (Table 1). Therefore, the choice of imaging
modality for molecular imaging depends on the kind and
location of the cellular or molecular event that needs to be
monitored, as well as the biological questions that need to be
answered [4–6, 9].
Conventional radiography, CT, ultrasound and MRT provide
high-resolution images at the anatomical level, whereas mor-
phological information provided by nuclear and optical imaging
methods are limited, because they are based on the detection of
a signal coming from a radiolabelled or ﬂuorescent imaging
agent. Therefore, when nuclear or optical imaging methods are
used it is beneﬁcial to combine them with imaging modalities
FIG. 2. Types of imaging agents. The most commonly used imaging agents are non-speciﬁc, i.e. they do not bind to a speciﬁc
molecular target. These probes have compartmental distributions and can be used for imaging changes in blood volume, perfusion and
blood ﬂow. In contrast, targeted and activatable probes interact with speciﬁc targets and therefore make it possible to image biological
processes at the cellular or molecular level. Targeted probes bind to speciﬁc targets, such as receptors, and can be used to image
receptor expression and distribution (e.g. of cytokine receptors). Activatable probes are activated after interaction with a speciﬁc
target. A number of activatable probes have been developed to non-invasively image, for instance, the activity of matrix-degrading
enzymes such as MMPs or cathepsins. Adapted from [9].
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providing detailed information at the anatomical level in order
to combine anatomical and functional information [4–6, 9].
The major limitation of conventional radiography and CT
in molecular imaging is their low inherent sensitivity for
label detection. In order to produce detectable contrast, large
quantities of a contrast agent at the target site are necessary.
Furthermore, the adverse effects of ionizing radiation can be
restrictive, especially when repeated imaging is required. At
present, the main value of X-ray-based methods for molecular
imaging is the function of CT as a complementary modality to
nuclear or optical imaging, as it provides high-resolution images
at the anatomical level. In contrast to X-ray-based methods,
ultrasound has been successfully advanced so that it can go
beyond anatomical imaging: Doppler ultrasound and colour-
coded duplex sonography enables measurements of blood ﬂow,
direction and speed. Furthermore, the development of targeted,
acoustically reﬂective contrast agents has added molecular
imaging capabilities, as evidenced by several experimental
studies. Ultrasound is very sensitive for label detection, but
achieving sufﬁcient stability of such echogenic formulations is
difﬁcult (see the following section). Moreover, spatial resolution
of ultrasound rapidly decreases with depth and therefore
sonography does not provide as much detail about deeply
located structures. MRT has a particular advantage for use in
molecular imaging: information at the anatomical and molecular
levels can be recorded simultaneously, as shown in numerous
experimental approaches. Because MRT does not achieve the
sensitivity of nuclear or optical methods, it necessitates higher
amounts of contrast agent at the intended target to provide
sufﬁcient contrast. In addition to the high complexity of such
probes (see the following section), this is one of the reasons why
the design of MRT-based molecular imaging probes remains a
challenge [4–6, 9].
Exquisite sensitivity, especially for PET, which is even more
sensitive than SPECT, is the primary advantage of nuclear
imaging methods. Also advantageous is their ability to provide
quantitative measurements. The limiting factor is low spatial
resolution, which can make it difﬁcult to assign the signal to
a speciﬁc anatomical–morphological structure, a disadvantage
which can be partly compensated for by combining nuclear
imaging techniques with CT. Like nuclear imaging techniques,
optical imaging methods are very sensitive. Their major short-
coming is low spatial resolution and primarily limited depth
penetration, due to light scattering and absorption in tissue.
For imaging superﬁcial tissues located at outer surfaces (e.g.
skin lesions and arthritic ﬁnger joints) or at inner surfaces by
using endoscopic devices (e.g. gastrointestinal lesions), optical
imaging can provide a fast and inexpensive method, with
relatively simple instrumentation requirements [4–6, 9].
In recent years, imaging instrumentation dedicated to
small animal imaging has also become available for all major
clinical modalities (microCT, small animal ultrasound systems,
microMRI, microSPECT, microPET), as well as combinations
of different imaging modalities (e.g. microSPECT/CT or
microPET/CT). Since clinical systems are usually available in
larger hospitals and small animal imaging systems often require
TABLE 1. Main features of major imaging modalities and their role in RA
Imaging technique Advantages Disadvantages Role in RA
Conventional radiography High resolution (a few m) 2-dimensional Widely used
No depth limit Low soft tissue contrast Good delineation of bone erosions
Fast, low costs Shadowing and joint space narrowing but
Radiation limited to visualization of non-osseous
Low sensitivity for label detection features of disease
X-ray computed High resolution (tens of microns) Low soft-tissue contrast Limited use in clinical practice
tomography (CT) No depth limit Radiation
3-dimensional Low sensitivity for label detection
Ultrasound High resolution
(surface: tens of microns)
Low resolution (depth: centimetres) Increasing use because of its superiority
Real time; repeatability Depth limit to clinical examination and CR in
Low costs Shadowing detecting joint erosions and its versatility
High sensitivity for label detection Documentation of ﬁndings
Operator-dependent
Magnetic resonance High resolution
(less than 100 microns)
Limited to imaging osseous Increasing use because of its
tomography (MRT) No depth limit features of disease superiority to clinical examination and
3-dimensional High costs, slow CR in detecting joint erosions
Good soft-tissue contrast Medium sensitivity for label detection
Nuclear imaging No depth limit Low resolution (a few mm) Few studies
(SPECT, PET) 3-dimensional Limited information at
Quantiﬁable anatomical level
High sensitivity for label Radioactivity
detection High costs, especially PET
Imaging at molecular level
Fluorescence 3-dimensional (FMT) Low resolution (1mm) Currently limited to animal models
imaging (FRI, Fast, low costs Depth limit (FRI, a few mm;
FMT) Low costs FMT up to 10 cm)
High sensitivity for label 2-dimensional (FRI)
detection Limited information at
Imaging at molecular level anatomical level
Bioluminescence imaging Fast, low costs Low resolution (1mm) Animal models only
High sensitivity for label 2-dimensional
detection Limited information at
Imaging at molecular level anatomical level
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a high initial investment, there is also a parallel trend to adapt
clinical scanners to the needs of small animal imaging, for
instance by using dedicated animal coils in MRT [10]. Various
instrumentations also exist for small animal optical-based
imaging [11].
Recent advances in molecular imaging
Various imaging agents with molecular speciﬁcity (targeted and
activatable probes) have been designed for ultrasound, MRT,
nuclear and optical imaging. They can be used to image cellular
and molecular events, such as gene expression, angiogenesis,
apoptosis and cell trafﬁcking [4–6, 9].
Targeted imaging agents
Targeted ultrasound imaging agents have been developed by
conjugating afﬁnity ligands to acoustically reﬂective particles,
including microbubbles and liposomes. For clinical purposes,
these agents have been developed for imaging, thrombosis,
endothelial cell adhesion molecules, tissue factors, activated
leucocytes and angiogenesis. Among the potential limitations
of ultrasound-targeted contrast agents are their stability and the
relatively large size of such formulations (>250 nm), limiting
their ability to overcome biological barriers [12, 13].
Targeted MRT agents are based on superparamagnetic
iron oxide nanoparticles or on lanthanide chelates such as
gadolinium-DTPA. Superparamagnetic iron oxide particles
usually consist of a crystalline iron oxide core containing
thousands of iron atoms, surrounded by a polymer coating.
The individual formulations vary in size (10–300 nm), coating
(e.g. dextran or polyethyleneglycol) and magnetic properties (R1,
R2, susceptibility). Efﬁcient targeting also requires strategies
such as caging of the dextran coat. Dextran caging has been
achieved by cross-linking the coating and resultant particles
(cross-linked iron oxide, CLIO), and is being used as a basis for
targeting receptors, integrins or speciﬁc cells. Lanthanide chelates,
such as gadolinium-DTPA, are also used as MRT contrast
agents, but their lower intrinsic relaxivity requires larger-
sized nanoparticle constructs, such as polymerized liposomes,
dendrimers and perﬂuorocarbon nanoparticles, to achieve high
magnetic payloads and longer intravascular lifetimes. However,
these agents have been successfully used to image angiogenesis,
progenitor cells and thrombotic events in vivo [14, 15].
Targeted nuclear imaging agents have been primarily
developed for vascular processes and targets, including apoptosis
and angiogenesis, viability, atherosclerosis and thrombosis.
Targeted nuclear agents can also visualize gene expression, for
example by targeting a gene-transcribed extracellular protein or
by detecting expression of a reporter gene such as herpes simplex
virus thymidine kinase (HSV-Tk). In mammalian cells, exo-
genous HSV-Tk phosphorylates acylguanosine residues, gener-
ating biological signal ampliﬁcation when the phosphorylated
radioisotopes are intracellularly trapped [16, 17].
A number of targeted optical imaging agents have been
described, including those with speciﬁcity for receptors (e.g. for
folate, somatostatin) or speciﬁc ligands primarily for imaging
cancer cells or apoptotic cells. Using ﬂuorochromes such as
Cy5.5 or Cy7, which absorb and emit light in the near-infrared
bandwidth, minimizes autoﬂuorescence and maximizes tissue
penetration because the major absorbers, haemoglobin and
water, have their lowest absorption coefﬁcients in the near-
infrared region. Optical imaging is a rapid and inexpensive
method of visualizing biological events. The use of spectrally
different ﬂuorochromes allows the concurrent imaging of
multiple targets (multichannel imaging) [11].
Activatable agents
Activatable MRT agents are already detectable in their native
form, but target interaction causes a change in relaxivity
(‘activation’) which can be detected by MRT. Several probes
based on lanthanide chelate and superparamagnetic nanoparti-
cles with different molecular speciﬁcities have been developed
in recent years, e.g. to visualize enzyme activity, different afﬁnity
targets such as E-selectin, or to evaluate molecular interactions
(DNA–DNA, protein–protein, protein-small molecule) [18–20].
A number of activatable optical imaging agents have
been developed for in vivo imaging of protease activity. The
ﬂuorescence of these probes is quenched until activation
by enzymatic cleavage, which results in a marked increase
in the ﬂuorescence signal. Various probes with different speci-
ﬁcities (e.g. cathepsins, MMPs, caspases) have been tested
and characterized for the imaging of cancer invasiveness and
apoptosis [11].
Molecular imaging in RA
Potential targets for molecular imaging in RA involve all aspects
of its pathophysiology, inﬂammation and destruction operative
in the different compartments of the human joint and in the
respective animal models. In addition, the detection, tracking
and monitoring of molecules driving or inhibiting the arthritic
process are also of considerable interest for the development of
novel therapeutic strategies. Studies using molecular imaging
agents in RA are currently limited to nuclear and optical
imaging methods.
Nuclear imaging approaches
Recent strategies to target and visualize speciﬁc processes in
arthritic synovium using nuclear imaging approaches include
targets that mark soluble factors, cells or surface molecules, or
the activation of cells and apoptosis, or that indicate dynamic
processes such as proliferation [21–30].
Interleukin-1 and TNF are key molecules driving arthritis and
inﬂammation in RA synovium, and numerous groups have
successfully used radiolabelled interleukin-1 receptor antagonist
(123-J IL-1ra) [21] and anti-TNF monoclonal antibody [22] to
localize these molecules in synovium. Using leucocytes labelled
with 99mTc-hexamethylpropylene amine oxime (99mTc-
HMPAO), synovial inﬂammation could be visualized, and
estimation of disease activity was also possible [23]. In a similar
approach, 99mTc-E-selectin binding peptide could localize this
important adhesion molecule [24]. Of interest, 99mTc-anti-E-
selectin-Fab can be used successfully to image synovitis with
better speciﬁcity than 99mTc-HDP bone scanning [25].
Methyl-11C-choline is a marker of cellular proliferation.
Based on the knowledge that choline is a precursor for the
biosynthesis of phospholipids (in particular phosphatidylcho-
line), which is the essential component of all eukaryotic
cell membranes, and that the proliferative changes occurring
in arthritic synovium enhance membrane synthesis, which
increases the demand for phospholipids, this molecular marker
was able to indicate general proliferative activity in arthritic
synovium [26]. Similarly, based on the fact that maintenance
of arthritis requires a considerable amount of energy,
enhanced glucose metabolism could be successfully imaged by
18F-ﬂuorodeoxyglucose (FDG) PET imaging (Fig. 3) [26–29]. In
addition, a recent study showed that 18F-FDG PET can assess
the metabolic activity of synovitis and even measure disease
activity in RA [29]. Moreover, the volume of enhancing pannus
(VEP) was determined from fat-suppressed MRIs. VEP and
FDG uptake were closely correlated, as were changes in VEP
and standardized uptake volume. VEP and FDG uptake were
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strongly associated with clinical ﬁndings in wrists but not with
treatment outcomes. Contrast material-enhanced MRI and
PET allow quantiﬁcation of volumetric and metabolic changes
in joint inﬂammation and comparison of efﬁcacies of anti-
inﬂammatory agents [28]. In contrast, the use of radiolabelled
annexin V to image apoptosis, which may be used for moni-
toring therapies that induce reduced proliferation and apoptosis,
is also feasible [30].
Optical imaging approaches
A number of recently published studies in experimental settings
have shown the potential of optical-based imaging technologies
(ﬂuorescence reﬂectance imaging and bioluminescence imaging)
to evaluate cellular and molecular events in arthritis. These
approaches include non-invasive monitoring of inﬂammatory
cells or transcription factors involved in disease, imaging gene
transfer, and apoptosis or the activity of enzymes involved in
joint destruction to monitor treatment response [31–36].
Using antimacrophage monoclonal antibodies (anti-F4/80)
labelled with a near-infrared ﬂuorochrome, Hansch and
colleagues [31] demonstrated the feasibility of ﬂuorescence
reﬂectance imaging in visualizing inﬂammatory cells in arthritic
joints in vivo in a murine arthritis model. Fluorescence reﬂec-
tance imaging showed accumulation of the imaging agents in
the inﬂamed knee joints and, to a lesser extent, in the
contralateral (non-arthritic) knee joints. In this approach,
monitoring of these inﬂammatory cells was optimal until 12 h
after injection of the ﬂuorochrome, but ﬂuorescence measure-
ments could be realized over a period of 7 days. Carlsen et al.
have developed transgenic mice that express luciferase under
the control of the transcription factor NF-B, enabling non-
invasive real-time bioluminescence imaging of NF-B activity
in intact animals. In a mouse model of RA, joints affected
by arthritis produced strong NF-B activity, resulting in a high
signal intensity that could be imaged non-invasively. Since
NF-B is an important factor in the pathogenesis of RA, this
model is a helpful tool in arthritis research [32].
Molecular imaging techniques can also be used for the
visualization of disease- or therapy-related cells in living organ-
isms. One of the most recent examples is the tracking of
genetically altered cells in an adoptive gene therapy setting
in which T cells were transduced in a murine model for RA.
To be able to demonstrate the ability of injected cells to
migrate preferentially into the inﬂamed articular tissue, in vivo
bioluminescence imaging was applied. This technology allows
longitudinal analyses; for example, adoptively transferred cells
can be monitored in individual animals in real time on
consecutive days for extended periods of time without the need
to kill the animals. For this purpose, the cells of interest were
transduced to express the enzyme luciferase prior to the transfer.
Then, the animals received the luciferase substrate luciferin.
Conversion of luciferin to oxyluciferin by luciferase from
transferred cells generated light that could be detected sensitively
by a camera system. Light intensity was visualized using a false-
colour scale in which blue indicated low and red indicated high
intensity, and the generated coloured spots were superimposed
onto a grey-scale image of the animals that was obtained under
weak illumination in the otherwise light-tight image chamber
of the camera system. The coloured spots indicated the local-
ization of the adoptively transferred cells (and the encoded
gene products) within the different tissues of the animals.
Figure 4 illustrates a bioluminescence images after adoptive
gene transfer [33, 34].
In very recent approaches, we showed that near-infrared
ﬂuorescence imaging with a ﬂuorescence reﬂectance imaging
system can be used for non-invasive imaging of the treatment
response in mouse models of RA using ﬂuorescence-labelled
annexin V as a biomarker of apoptosis and an enzyme-
activatable ﬂuorescent imaging probe as a marker of joint
FIG. 3. 18F-Flurorodeoxyglocose (FDG) positron emission tomography (PET) imaging in arthritis. Images of a healthy control subject
(A and B) and an RA patient with active RA (C and D). Normal tracer distribution in knee (A) and in hand and wrist (B). Tracer
distribution in rheumatoid knee (C) and wrist (D). The ﬁgure shows that 18F-FDG PET can assess the high metabolic activity of
inﬂamed joints. Reprinted from [29].
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destruction. Annexin V binds with high afﬁnity to phos-
phatidylserine, a constitutive membrane phospholipid that is
normally restricted to the inner leaﬂet of the plasma membrane
lipid bilayer but is selectively exposed on the surface of cells as
they undergo apoptosis. Arthritic paws of mice treated with
methotrexate (MTX) showed a signiﬁcantly higher ﬂuorescence
intensity than arthritic paws of untreated mice and non-arthritic
paws of MTX-treated mice. Thus, monitoring the uptake of
ﬂuorescence-labelled annexin V in arthritic paws by ﬂuorescence
imaging may provide a method of assessing the treatment
response to antirheumatic drugs such as MTX, a response which
was readily quantitated with simple instrumentation and which
occurred before conventional measurements of the treatment
response [35].
In another approach, we used an enzyme-activatable near-
infrared ﬂuorescence imaging agent and ﬂuorescence reﬂectance
imaging to image protease activity for the non-invasive
monitoring of the treatment response. Since matrix-degrading
proteases such as cathepsins and MMPs are key players in joint
destruction, we hypothesized that these enzymes would be
suitable targets to visualize treatment effects in vivo. To test
this principle, we used an imaging agent consisting of multiple
Cy5.5 ﬂuorochromes bound to a graft copolymer backbone
of polylysine. Due to interactions between the ﬂuorochromes,
ﬂuorescence quenching occurs. Therefore, the probe is relatively
non-detectable in its native injected state. Enzymatic cleavage of
the backbone in vivo by enzymes such as cathepsin B releases
Cy5.5 and results in a signiﬁcant increase in ﬂuorescence
(activation). After intravenous injection of the imaging probe,
arthritic toes and paws showed a high ﬂuorescence intensity.
In MTX-treated animals, a signiﬁcantly lower ﬂuorescence signal
was observed (Fig. 5). Using this experimental strategy, we could
demonstrate not only that enzyme-activatable imaging probes
can be used to visualize protease activity in vivo, but also that
the reduction in activity following MTX therapy can be used to
monitor the response to treatment [36].
Outlook
Parallel to our continuously increasing knowledge of molecular
actions and interactions within the arthritic joint and its cellular
and subcellular components, the various imaging techniques that
have been developed in recent years will not only allow better
identiﬁcation, visualization and quantitation of key processes of
the disease but most likely will also provide substantially
improved capabilities for early diagnosis of RA, monitoring of
treatment efﬁcacy and more effective therapies.
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